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ARTICLE
Sea turtle fibropapilloma tumors share genomic
drivers and therapeutic vulnerabilities with human
cancers
David J. Duffy 1,2,3, Christine Schnitzler1,4, Lorraine Karpinski5,6, Rachel Thomas1, Jenny Whilde1,
Catherine Eastman1, Calvin Yang1, Aleksandar Krstic7, Devon Rollinson1, Bette Zirkelbach5, Kelsey Yetsko1,
Brooke Burkhalter1 & Mark Q. Martindale 1,4
Wildlife populations are under intense anthropogenic pressures, with the geographic range of
many species shrinking, dramatic reductions in population numbers and undisturbed habitats,
and biodiversity loss. It is postulated that we are in the midst of a sixth (Anthropocene) mass
extinction event, the first to be induced by human activity. Further, threatening vulnerable
species is the increased rate of emerging diseases, another consequence of anthropogenic
activities. Innovative approaches are required to help maintain healthy populations until the
chronic underlying causes of these issues can be addressed. Fibropapillomatosis in sea turtles
is one such wildlife disease. Here, we applied precision-medicine-based approaches to profile
fibropapillomatosis tumors to better understand their biology, identify novel therapeutics, and
gain insights into viral and environmental triggers for fibropapillomatosis. We show that
fibropapillomatosis tumors share genetic vulnerabilities with human cancer types, revealing
that they are amenable to treatment with human anti-cancer therapeutics.
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W ild sea turtle populations, which are already in dangerof extinction (http://www.iucnredlist.org/), are underincreasing threat from a potentially fatal virulent
tumor, fibropapillomatosis (Fig. 1a). These tumors are under-
mining turtle conservation efforts within Florida (FL, where
fibropapillomatosis was first recorded) and circum-globally, with
the disease having spread throughout equatorial and sub-
equatorial equatorial regions1–9. Green sea turtles (Chelonia
mydas) are the species most commonly and severely afflicted with
fibropapillomatosis (Fig. 1), but it also occurs in all other sea
turtle species4–7,10–12, and evidence suggests that its geographic
range is spreading6,8,9,13. Fibropapillomatosis is now being
reported from more northern latitudes where it has never been
previously recorded6. The etiology of fibropapillomatosis is not
fully understood, but the disease has a combination of viral and
environmental cofactors5. A large number of oncogenic viruses
have been reported in terrestrial and aquatic wildlife and
domestic animals14,15. Meanwhile, in humans, the number of
cancer incidences identified as attributable to pathogens has tri-
pled in only 4 years16,17, now accounting for 15% of all human
cancers. Furthermore, emerging infectious disease events in
humans are dominated by zoonoses (diseases transmitted to
humans from animals, 60.3%), with the majority of these (71.8%)
originating in wildlife18–20. Many emerging infectious diseases
(25–44%) are viral or prion in nature18,19,21,22. It is clear that
vertebrate virus-borne disease can spread through the marine
environment, and that anthropogenic effects (e.g., habitat
degradation) are largely responsible for the increased rate in the
emergence of infectious diseases4,18,23–25. Therefore, a more
concerted effort to improve our understanding of pathogen-
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Fibropapilloma tumor 2 (mj)
Control skin (sp)
Fibropapilloma tumor 1 (sp)
Fig. 1 Fibropapillomatosis tumors and differential transcript expression. a Fibropapillomatosis-afflicted green sea turtles (Chelonia mydas). Left and center:
Turtles at the Whitney Sea Turtle Hospital, FL, prior to tumor removal surgery. Right: High magnification image of a fibropapilloma tumor, which was
profiled by RNA-seq. b Principle component analysis of patient-matched control and fibropapillomatosis RNA-seq samples. Upon admittance to the
hospital, Swoope (sp) had a tumor score of class 3 (Hawaii classification system)105, and severe (FPI > 185.5) (Southwest Atlantic classification system)
106, while Major (mj) had a tumor score of class 2105, and moderate (FPI= 81.5)106. c Overlap of transcripts differentially expressed in fibropapillomatosis
tumors, independently called by DESeq2 and EdgeR from the RNA-seq data. Area-proportional Venn diagrams were generated using BioVenn (http://
www.biovenn.nl/)107. Transcripts were considered to be DE if passing the following cut-offs: false discovery rate (EdgeR) or adjusted p-value (DESeq2) of
<0.05 and log2 fold change of >2 or <−2
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induced cancers in wildlife, including potential exacerbating
effects of human coastal land use, is crucial for enhancing both
human and wildlife health.
Despite fibropapillomatosis first being reported in the late
1800s/early 1900s, and having reached panzootic levels in the
1990s1–3,5,6,26, practically nothing is known about the host
molecular events/genes driving the tumors. Furthermore, the viral
dynamics of fibropapillomatosis are poorly understood. Trans-
missibility of the tumors was experimentally proven in 199527.
Fibropapilloma tumors are transmissible to fibropapillomatosis-
free turtles via injection of tumor-derived freeze–thawed and
filtered sub-cellular fractionations, indicating a viral agent27. The
inability to culture the responsible virus in a lab setting28,29 has
meant that Koch’s postulates remain unfulfilled and viral causa-
tion has yet to be definitively proven. However, a number of
studies have shown fibropapilloma-associated turtle herpesvirus
(FPTHV), also known as chelonid herpesvirus 5 (ChHV5) and
chelonid fibropapilloma-associated herpesvirus (CFPHV), to be
associated with fibropapillomatosis globally5,10,27,30,31, and the
genome of this virus has been partially sequenced32,33. Con-
versely, high levels of ChHV5 DNA have been detected in clini-
cally healthy marine turtles30,34. Recently a step toward
completing Koch’s postulates was made with the successful
in vitro growth of ChHV5, in tumor cells cultured in a replica
complex three-dimensional structure of turtle skin, including
both fibropapilloma tumor fibroblasts and turtle keratinocytes35.
ChHV5 appears to be a virus upon which oncogenic potential
is conferred by a form of external environmental perturbation.
This is indicated by the widespread presence of ChHV5 in
clinically healthy turtles, including in regions where fibropa-
pillomatosis has never been observed (e.g., Europe) and in non-
tumor tissues of fibropapillomatosis-afflicted turtles7,30,34,36,37.
Furthermore, phylogenetic reconstruction analyses have shown
that ChHV5 has been present in sea turtles well before the out-
break of fibropapillomatosis, having co-evolved with its turtle
hosts5,36,38–40. Current estimates for the virus diverging to
becoming specific to marine turtles range from hundreds to
millions of years, yet tumors are thought to be only a relatively
recent phenomenon5,36,38–40. Strong correlative evidence
suggests that localized human-induced environmental changes
are responsible for conferring oncogenic potential upon
ChHV55,41–44. Fibropapillomatosis rates are extremely high in
many habitats degraded by human activity, yet almost absent
from neighboring more pristine areas5,43,44.
Currently, surgical removal is the primary treatment for turtles
with fibropapillomatosis, but one study showed that almost 60%
of tumors (in 38.5% of cases) regrew post-surgery7. The regrowth
occurs within an average of 36 days, but since records are only
available for the relatively short period of captive rehabilitation, it
is likely that the true occurrence of regrowth is much higher.
Additionally, there is currently no effective treatment for turtles
presenting with internal tumors (which can result in organ fail-
ure), detectable by X-ray, magnetic resonance imaging (MRI), or
computerized axial tomography (CAT) scanning, with such tur-
tles usually having to be euthanized. Therefore, novel therapies
are urgently needed to enhance the rehabilitation outcomes of
turtles with fibropapillomatosis.
Although the viral nature of fibropapilloma tumors has been
widely, if not conclusively, investigated, the role of the host
molecular events in driving these tumors has been largely over-
looked. Given that oncogenic viruses play their most critical role
in the very early stages of tumor development, primarily in the
transformation of host cells, the scope of anti-viral treatments for
tackling well-established tumors is severely limited45. This fact is
highlighted by the hit-and-run hypothesis of viral oncogenic
transformation, whereby after inducing the malignant conversion
of host cells, viruses are no longer necessary for the maintenance
of the malignant state and may no longer be physically present in
tumors46. Therefore to improve our understanding and treatment
of fibropapillomatosis, it is particularly important to examine the
molecular mechanisms present in host cells, which drive the
growth of established tumors. That turtles tend to present to
rehabilitation facilities in the more advanced stages of tumor
growth highlights the critical knowledge gap in our under-
standing of fibropapillomatosis.
Here, we demonstrate the applicability of precision wildlife
medicine4 to improving animal health and advancing wild animal
clinical care. In order to determine the molecular signaling events
responsible for driving fibropapilloma tumor growth in green sea
turtles (C. mydas), we employed precision medicine approa-
ches47–49, previously honed in the field of human oncology. This
included next-generation Illumina RNA sequencing (RNA-seq)
transcriptomic profiling and computationally-based systems-level
analysis. We show that in established tumors, there is minimal
ChHV5 expression; rather tumors are primarily driven by altered
host gene expression, leaving them vulnerable to anti-cancer
therapeutics. We thereby advanced the study of host molecular
drivers of chelonid fibropapilloma tumors from their current pre-
genetic era, bypassing the candidate gene-centric approach
straight into the modern genomics era, providing a solid under-
standing of the basic cell signaling pathways that drive tumor
growth, thus enabling the identification of therapeutic targets for
fibropapillomatosis treatment.
Results
Fibropapillomatosis transcriptomics reveals altered host gene
expression. We transcriptomically profiled tumor tissue, surgi-
cally removed by laser resection as part of the turtle’s rehabili-
tative care, and compared global gene expression to that of
biopsies from non-tumor areas of the same turtles. Ten RNA
samples from two juvenile green turtles (C. mydas), which had
stranded in northern FL were used for sequencing (Fig. 1b). The
early development phase of fibropapilloma tumors is associated
with proliferation of epidermal cells, while later growth is asso-
ciated with proliferation of the dermal layer5. Therefore, in order
to obtain representative untransformed control tissue, we profiled
skin punch biopsies containing epidermis, dermis, and sub-
cutaneous tissue. Principle component analysis of the RNA-seq
data confirmed that non-tumor samples grouped separately from
tumor samples (Fig. 1b). A de novo transcriptome was assembled
from the sequencing reads using Trinity v2.1.150. The tran-
scriptome was generated using Trinity’s unguided function, to
ensure that any tumor-specific or viral transcripts present would
not be filtered out during transcriptome generation, and given
that currently only a draft C. mydas genome exists. The de novo
transcriptome consisted of 266,069 transcripts, with an N50
length (the largest length such that 50% of all base pairs are
contained in contigs of this length or larger) of 1562 bp. Pair-wise
comparison of the tumored and non-tumored tissue revealed that
4345 transcripts were differentially expressed (DESeq2, adjusted
p-value cut off of 0.05 and with a log2 ± 2 fold change applied)
(Fig. 1c), with the majority of these (83%) being upregulated in
the tumors (Supplementary Figure 1A, B). When EdgeR was used
to independently call differentially expressed (DE) transcripts,
there was a strong overlap between the transcripts called as DE
between DESeq2 and EdgeR (Fig. 1c), adding confidence that
these are genuine DE transcripts and not artifacts of the com-
putational analysis. We confirmed the upregulation of Fibronectin
Type III Domain Containing 1 (FNDC1, a cancer-associated
gene51), a top DE transcript (Fig. 2a), in an extended panel of
fibropapillomatosis tumor samples (14 control and 67 tumor
samples) by qPCR (Fig. 2b).
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RNA-seq reveals a paucity of ChHV5 viral transcripts within
tumors. Having confirmed the differential expression of host
genes within the tumors, we next examined ChHV5 viral
expression by blasting the de novo transcriptome against the
ChHV5 partial genome33 [GenBank accession number:
HQ878327.2]. Although ChHV5 has been associated with fibro-
papillomatosis and ChHV5 DNA is readily detectable within
tumors5,31, there was an almost complete lack of viral transcripts
within the RNA-seq samples, with only four ChHV5 transcripts
being detected, three of which were related transcript variants
(Fig. 2c, Supplementary Table 1). Interestingly, no viral tran-
scripts were detected in the non-tumor tissue samples, being
specific to the tumor samples (Fig. 2c). However, even in the
tumors, there was a paucity of viral transcripts expressed, with the
transcripts related to only two regions of the genome; the F-
LANA/HP2 and the HP3/HP4 regions (Fig. 2c). Expression levels
of these transcripts were also relatively low (viral expression
range: 0–1.344 trimmed mean of M values (TMM). The range of
expression for all transcripts [viral and host] was 0–125,636.734
TMM, with the average expression level of all transcripts across
samples being 4.608 TMM.) Within the ChHV5 genome, the
coding region of the F-LANA and HP2 genes overlap, one tran-
script from the RNA-seq mapped to this region (Fig. 2c and
Supplementary Table 1). However, for the HP3/HP4 region, three
related but distinct transcript variants were called (Supplementary
Table 1), one within the HP3 gene and two mapping to the region
between the HP3 and HP4 genes (Fig. 2c and Supplementary
Table 1). Due to a genomic duplication event33, all four viral
transcripts detected map to two locations within the ChHV5
genome, at both the terminal and internal repeat regions
(Supplementary Table 1).
To confirm the paucity of viral transcripts independently of
our de novo transcriptome, we also aligned the reads for each
sample against the ChHV5 genome. As with the de novo
transcriptome analysis, direct mapping to the ChHV5 genome
also showed viral reads predominantly aligning to the terminal
and internal repeat region around the F-LANA, HP2, HP3, and
HP4 genes (Supplementary Figure 1C). F-LANA is a latency-
associated nuclear antigen gene, which promotes viral latency by
suppressing viral transcription and facilitating DNA replication52.
The detection of the F-LANA expression along with the paucity of
other ChHV5 transcripts suggests that ChHV5 is latent within
these tumors. Viral latency would indicate that any causative role
for ChHV5 in fibropapillomatosis tumorigenesis occurs early, and
that the virus does not continue to drive the growth of established
tumors.
Fibropapillomatosis has a neuronal signature and similarity to
human cancer. To determine the molecular mechanisms driving
fibropapillomatosis tumors, we took the top 600 (300 per direc-
tion of regulation, Supplementary Table 2) statistically significant
DE transcripts (DESeq2 analysis, adjusted p-value cut-off of 0.05
and with a log2 ± 2 fold change applied, the adjusted p-value
























p-value range: 3.5E-119 to 2.17E-42
























































































































Fig. 2 Differentially expressed host (C. mydas) and viral (ChHV5) transcripts. a Top ten statistically significant upregulated and top ten downregulated
transcripts in fibropapillomatosis tumors compared with control tissue. Transcript expression values underlying the differential expression analysis are
provided in Supplementary Table 4. Differential expression p-values reported are adjusted p-values, generated by DESeq2 by a Wald test followed by
Benjamini–Hochberg correction. b Relative expression of Fndc1 mRNA in fibropapillomatosis tumor and control samples, as detected by RT-qPCR. Data for
66 tumor samples and 14 control samples. The p-value was calculated by t-test. c Expression levels (trimmed mean of M values, TMM) of ChHV5 viral
RNA de novo transcripts across the ten RNA-seq samples. Related transcript variants are denoted by t.1, t.2, or t.3
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3.52E−119 to 3.15E−14 and 1.33E−105 to 3.35E−05, respec-
tively), determined their closest characterized homolog using
BLASTn (https://blast.ncbi.nlm.nih.gov/Blast.cgi)53, and per-
formed systems level analysis. Network analysis of these tran-
scripts (STRING database v10.5, http://www.stringdb.org/)54
revealed a highly interconnected network, which was strongly
enriched for neuronal-related genes (Fig. 3a, b), with nervous
system development and neurogenesis gene ontology (GO) terms
being strongly enriched (FDR padj.= 2.89E−12 and 2.03E−11,
respectively).
Protein-protein interaction map of top DE transcripts
Nervous system development related nodes highlighted
(Tumor vs. Control)
Nervous system development GO term:
78 nodes present




































































































































































































































































































































Nervous system development related nodes DE transcripts (listed in order of p -value) 
(Tumor vs. Control)
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We next performed Ingenuity Pathway Analysis (IPA,
https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis/)55, which revealed that fibropapilloma tumors
share a striking similarity to a number of human cancers
(Fig. 4a–c). Human basal cell carcinoma (BCC) signaling was the
top-ranked signaling pathway in fibropapillomatosis tumors
when compared with non-tumored control tissue
(p= 1.77E−10, Fig. 4a), with BCC signaling being activated
(Fig. 4b). Mirroring the network analysis findings, axonal
guidance signaling was the second most significant pathway
identified (p-value= 2.45E−10) (Fig. 4a). In addition to their role
in neuronal development and neuronally-derived tumors (e.g.,
medulloblastoma and neuroblastoma), axonal guidance genes
have been shown to be involved in driving tumorigenesis in a
range of other non-neuronally-derived human cancer types such
as pancreatic cancer56. Human embryonic stem cell pluripotency
signaling was the third most highly ranked pathway (p= 2.34E
−08), in line with the fibropapillomatosis tumors consisting of
less differentiated more stem-like cells, as is the case in human
tumors57,58.
Cancer and neuronal disease terms also topped the disease GO
terms analysis (Fig. 4c and Supplementary Figure 1C), with
cancer growth, invasion, and metastasis terms being activated,
while cell death and apoptosis terms were inhibited (Supplemen-
tary Figure 1C), again consistent with fibropapillomatosis tumors
tending to have rapid growth rates, and a propensity for tens to
hundreds of tumors to develop on a single infected individual.
Strikingly, of the 334 unique genes (from the top 600 DE
transcripts) with homology to human genes, almost all of them
(321 genes) are associated with human cancer (Fig. 4c, p-value=
3.10E−06). This includes the upregulation of genes such as
ITGA5 (Supplementary Table 2), which are involved in virally-
mediated angiogenesis promotion in Kaposi’s sarcoma59.
IPA inferred transcriptional regulator (ITR) analysis, which
matches observed DE genes to known patterns of gene regulation
by specific transcriptional regulators55, revealed a highly inter-
connected network of regulators, governing the gene expression
changes seen in fibropapillomatosis (Supplementary Figure 1D).
The ITR analysis also suggested a number of potential novel
therapeutics for fibropapillomatosis treatment such as β-estradiol,
or inhibitors of a number of pathways including TGFβ, Wnt,
MAPK, and EGFR (Fig. 4d).
Wnt and SHH signaling regulate fibropapillomatosis, which
correlates with UV exposure. Our systems-level analysis identi-
fied shared molecular networks between sea turtle fibropapillo-
matosis and human BCC, including Wnt, BMP, and SHH
signaling. While being involved in a variety of other cancer
types60–66, Wnt and sonic hedgehog (SHH) signaling are a part of
a shared regulatory network in BCC and are differentially acti-
vated in fibropapilloma tumors (Fig. 5a, b). We confirmed that
Wnt5a was differentially expressed in a large panel of fibropa-
pilloma tumors, primarily being upregulated (Fig. 5c). Wnt5a is
an important regulator of both the Wnt/PCP and Wnt/β-catenin
pathways, playing a prominent role in neuronal stem cells and
nervous system development67,68, and is an important regulator
of tumorigenicity of many human cancers, including neuronal
derived ones62,67–72.
As BCC is a skin cancer with both genetics and ultraviolet
radiation (UV) exposure as risk factors, we investigated whether
any correlation between fibropapillomatosis incidence and high
UV exposure levels exists. Historical daily UV index (UVI) data,
dating from 1995 to 2015, were available for three coastal cities in
FL: Jacksonville (north FL), Tampa Bay (central FL), and Miami
(south FL) (http://www.ftp.cpc.ncep.noaa.gov/long/uv/cities/ and
http://www.cpc.ncep.noaa.gov/products/stratosphere/uv_index/uv_
annual.shtml). Despite fibropapillomatosis’s rapid circum-global
spread (including the Caribbean, Hawaii, Australasia, India, and
Africa), fibropapillomatosis has been much slower to spread to
more temperate latitudes, with northern FL (north of latitude 29°
N) remaining fibropapillomatosis-free until 2000, despite fibro-
papillomatosis being present in the FL Keys since before 19131–
3,6. Therefore, while fibropapillomatosis was present in the Miami
and Tampa areas for the entire duration for which UVI
recordings are available, the Jacksonville data cover the period
of the spread of fibropapillomatosis into northern FL (Fig. 6a).
There was a clear trend from north to south in the number of
days annually with extreme UV exposure levels (UVI > 11), and
the number of extreme UVI days has increased from 1995 to 2015
across all three FL sites. Between 1995 and 2015, both the total
number of green sea turtles (C. mydas) stranding in FL exhibiting
fibropapillomatosis and the percentage of all stranded C. mydas in
FL, which are afflicted with fibropapillomatosis has grown73
(Fig. 6b,c). The increasing incidence of fibropapillomatosis in FL
is in line with global fibropapillomatosis incidence trends6. We
next performed a linear regression analysis to determine whether
there was any correlation between the number of C. mydas
stranding with fibropapillomatosis each year and the number of
days of extreme UVI (average of all three sites) in the previous
year (Fig. 6d). UVI levels from the previous year were used due to
the recognized lag between UV exposure and skin cancer
development74. The analysis revealed that there was a mild
positive correlation between UVI exposure and the numbers of
stranded fibropapillomatosis-afflicted turtles (R2= 0.493), sug-
gesting that UV exposure may also be a risk factor for
fibropapillomatosis and a potential limiting factor accounting
for the relatively slow northward spread of fibropapillomatosis.
The observed level of correlation is relatively high, considering
that fibropapillomatosis is a multifactorial disease with viral and
other environmental factors likely contributing to disease
progression5.
5-FU post-surgical treatment mitigates fibropapillomatosis
tumor regrowth. We revealed that fibropapillomatosis shares
molecular characteristics with human BCC, for which a number
of effective therapies exist including the topical application of
fluorouracil (5-FU) onto affected skin regions. While 5-FU is used
in a number of human cancers, topical application is a first line
treatment in BCC75. Sixty percent of fibropapillomatosis tumors
regrow after surgical removal7, with surgery being the only widely
employed treatment option. As is the case in human oncology,
adjunct drug/chemotherapy treatment post-surgery is likely to
dramatically reduce tumor regrowth rates, thus the utility of 5-FU
Fig. 3 Transcripts differentially expressed in fibropapillomatosis are associated with nervous system development. a Protein–protein interaction map of the
top differentially expressed transcripts (RNA-seq) with homology to characterized human genes. Generated from the top 600 (300 per direction of
regulation) differentially expressed transcripts. Nervous system development-related nodes are highlighted by red shading. Network generated by the
STRING database54 (v10.5, http://www.stringdb.org), with the inbuilt KEGG pathway enrichment analysis tool applied to this network. b Fold change in
expression of the differentially expressed transcripts (RNA-seq) related to nervous system development (KEGG), listed in order of false discovery rate
(FDR, KEGG pathway enrichment analysis tool). Transcript expression values underlying the differential expression analysis are provided in Supplementary
Table 4
ARTICLE COMMUNICATIONS BIOLOGY | DOI: 10.1038/s42003-018-0059-x
6 COMMUNICATIONS BIOLOGY |  (2018) 1:63 | DOI: 10.1038/s42003-018-0059-x | www.nature.com/commsbio
as an adjunct therapy in fibropapillomatosis was assessed in eye
tumors.
Fibropapillomatosis tumors commonly occur in the eye region,
often arising from the conjunctivae or cornea5,7 (Fig. 7a). Eye
tumors can grow to a considerable size, obscuring vision. Given
the smaller surface area of eye tumors and the high level of
debilitation caused by them, these tumors are particularly suited
to topically delivered post-surgery chemotherapy to help prevent
tumor regrowth. Sixty-seven percent of turtles whose eye tumors
(ocular and periocular) were treated with surgery-only experi-
enced eye tumor regrowth (Fig. 7b, Supplementary Table 3), this










































































































































































































































































































































































































































































































































































































































































































































Top 50 canonical pathways of DE transcripts, ranked by p -value
(Tumor vs. Control)

















































































































































































































































































Canonical pathways of DE transcripts 







































































































































































































































































































































































































































p-value range: 1.09E-08 to 0.016
Estrogen rec. = estrogen receptor
Fig. 4 Pathway, disease gene ontology (GO) term, and transcriptional regulator analysis of the top 600 transcripts differentially expressed in
fibropapillomatosis tumors. a Top 50 canonical pathways of the fibropapillomatosis tumor differentially expressed transcripts (RNA-seq), as detected by
IPA, ranked by p-value (calculated by right-tailed Fisher’s Exact Test, with Benjamini–Hochberg correction). b Activation/inhibition z-scores of the
canonical pathways of the fibropapillomatosis tumor differentially expressed transcripts, as detected by IPA. c Activation z-scores of the top 25 disease-
associated GO terms of the fibropapillomatosis tumor differentially expressed transcripts (RNA-seq), as detected by IPA, ranked by p-value (calculated by
right-tailed Fisher’s Exact Test, with Benjamini–Hochberg correction). d Activation/inhibition z-scores of the inferred transcriptional regulators (ITRs) of
the fibropapillomatosis tumor differentially expressed transcripts (RNA-seq), as detected by IPA, ranked by p-value (calculated by right-tailed Fisher’s
Exact Test, with Benjamini–Hochberg correction). Legend of x-axis labels for Fig. 3a–c is also provided in Supplementary Table 5
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fibropapillomatosis tumors (regardless of body location) in other
studies, i.e., 60% of tumors re-growing7. However, when turtles
received 5-FU post-surgery (8 week 5-FU course, treated twice
daily with 1% topical 5-FU drops), only 18% of turtles
experienced eye tumor recurrence (Fig. 7b). The duration of
post-treatment follow-up varied as dictated by the individual
circumstance of each turtle (Supplementary Table 3), but was




















































Basal cell carcinoma KEGG pathway: FDR adj.
p -value = 1.64E-14
Network of Wnt, SHH and BMP pathway 





































































































































































































































Wnt, SHH and BMP-related DE transcripts (in top 600 DE, 300 per direction)
(Tumor vs. Control)










Fig. 5 Wnt, SHH, and BMP pathways in fibropapillomatosis tumors. a Left: Activation/inhibition z-scores of Wnt- and SHH-related IPA pathway analysis
findings of the fibropapillomatosis tumor differentially expressed transcripts (RNA-seq), p-values calculated by right-tailed Fisher’s Exact Test, with
Benjamini–Hochberg correction. Right: Interaction map of the 43 Wnt, SHH, and BMP pathway component and target genes differentially expressed in
fibropapillomatosis tumors (RNA-seq). Image generated using GeneMANIA (v3.5.0, http://genemania.org/)104. In addition to the 43 DE genes (nodes
with stripped shading), 20 closely functionally-related network components are also shown (nodes with uniform shading). Basal Cell Carcinoma KEGG
pathway score of the DE components of the network is shown below the network. b Fold change in expression of the differentially expressed transcripts
(RNA-seq) of Wnt, SHH, and BMP pathway-related genes. When more than one transcript of a gene was present in the top 600 DE genes (300 per
direction), each transcript is denoted by t1, t2, t3, etc. Differential expression p-values reported are adjusted p-values, generated by DESeq2, by a Wald test
followed by Benjamini–Hochberg correction. Transcript expression values underlying the differential expression analysis are provided in Supplementary
Table 4. c Relative expression of Wnt5a mRNA in a panel fibropapillomatosis tumor and control samples, as detected by RT-qPCR. Data for 66 tumor
samples and 13 control samples. The p-value was calculated by t-test
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Discussion
The increased rate of emerging diseases, and their exacerbating
negative effects on already stressed wild populations, poses an
additional burden on already elevated rates of population
reduction and species extinction4,18,23–25,76–81. The application of
omic technologies and human precision medicine approaches can
rapidly help alleviate the burden of such diseases and assist in
identifying causative factors, ultimately improving species con-
servation1. To this end, we applied next-generation tran-
scriptomic profiling and systems level analysis to
fibropapillomatosis tumors, revealing evolutionarily conserved
molecular mechanisms between fibropapillomatosis and human
cancer types such as BCC and neuronally-derived tumors. BCC
itself is known to have neuronal links, including the SHH path-
way and correlation between different BCC sub-types and neu-
ronal differentiation markers82. The neuronal signature of
fibropapillomatosis tumors suggests either extensive innervation
in these tumors, a previously unappreciated role of neuronal blast
cells in the origin of fibropapillomatosis tumors, or at least the
involvement of neuronal-related genes in fibropapillomatosis
growth. ChHV5 has previously been shown to reside in sea turtle
neuronal cells37, supporting a neuronal origin hypothesis. To
mitigate against any potential cell type-dependent gene expres-
sion biases and confirm our findings, our fibropapillomatosis
sequencing data should be compared against additional C. mydas
tissue-specific transcriptomic profiles as they become available.
Interestingly, we detected a paucity of ChHV5 transcripts in
our sequencing data. While, this is in line with suggestions that
ChHV5 remains latent in established tumors5,37 and is therefore
largely transcriptionally inactive, analysis of a wider variety of
fibropapillomatosis tumor transcriptomes is required to confirm
this finding. Our tumor profiling also suggests a number of
potentially promising novel therapeutic approaches. Adjunct 5-
FU treatment dramatically reduced the post-surgery regrowth
rate of eye tumors, demonstrating potential to reduce rehabili-
tation costs and burdens on individual turtles by negating the
need for additional rounds of surgery, and shortening the reha-
bilitation period. The ability of 5-FU to successfully reduce
fibropapillomatosis tumor recurrence rates reinforces the power
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+ Miami & Tampa: fibropapillomatosis present throughout entire time-series (present in Florida keys pre-1980, present
in Tampa from 1985 onwards).
^ Houston: fibropapillomatosis present from 2010 to current day, with growing prevalence.  



















































































Time-series of the number of days per year of extreme UV index (UVI)









Fig. 6 Putative fibropapillomatosis prevalence and ultraviolet (UV) radiation exposure link. a Number of days annually in the extreme UV index (UVI)
category recorded in Miami, Tampa Bay, Houston, and Jacksonville (data obtained from: http://www.ftp.cpc.ncep.noaa.gov/long/uv/cities/). Dates for the
occurrence of fibropapillomatosis in the vicinity of each UVI sampling site obtained from Hargrove et al.6. b Annual percentage of green sea turtles
stranding in FL afflicted with fibropapillomatosis, obtained from Foley et al.73. c Yearly averages of Jacksonville, Miami, and Tampa Bay UVI extreme days
annually, vs. annual fibropapillomatosis-afflicted green turtle strandings in FL. Correlation between fibropapillomatosis strandings and UVI conducted using
R2 linear regression analysis
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options for fibropapillomatosis treatment. While, 5-FU proved
effective for adjunct fibropapillomatosis eye tumor therapy, it
warrants further investigation in an independent, controlled
clinical study. Such a study should also investigate 5-FU as a
treatment for tumors in other body locations. However, as 5-FU
is a cytotoxic drug, and in BCC, it is only effective against low-
grade tumors75, more target therapies should also be trialed. Our
analysis also predicts a number of pathways for which more
targeted therapies exist, which are likely to have applicability as
both adjunct and first-line treatments. SHH and Wnt signaling
form an interconnected regulatory node in fibropapillomatosis
tumors, the targeting of which could potentially prove effective
for fibropapillomatosis treatment. Vismodegib (trade name, eri-
vedge), an inhibitor of the SHH receptor Smoothened (SMO), is
already in use clinically for the treatment of BCC83, while a
number of Wnt modulating therapies are being actively pursued
as anti-cancer treatments, currently at the clinical trial stage84.
Other targets include MAPK, TGFβ, and estrogen signaling.
These are already used in the treatment of a number of human
cancers, including neuronally-derived tumors, and their effec-
tiveness as fibropapillomatosis therapeutics should be further
investigated85–90. To fully achieve the promise of precision
medicine and move toward more targeted treatment, newer
generation therapeutics highlighted by our findings, such as vis-
modegib, should be trialed as anti- fibropapillomatosis
treatments.
The shared molecular drivers between fibropapillomatosis and
BCC suggested a putative role of UV radiation as one of the
environmental co-triggers of fibropapillomatosis. Interestingly,
Wnt and Metalloprotease signaling are two of the top DE path-
ways in fibropapillomatosis tumors. These pathways have been
shown to be regulated by UV exposure in human skin cells and
canine cornea, and mediate UV-induced abnormal morphogen-
esis in Hydra91–94. UV exposure has also been linked to systemic
immunosuppression95. Immunosuppression also occurs in turtles
with fibropapillomatosis, although it has not yet been proven if
this is a cause or a consequence of fibropapillomatosis5. Taken
together, further investigation into interactions between UV
exposure, regulation of host gene expression including immune-
related genes, and ChHV5 viral load are highly warranted. The
correlation between fibropapillomatosis incidence and extreme
UV conditions suggests that UV may be another risk factor for
fibropapillomatosis. Fibropapillomatosis is most prevalent during
green sea turtles’ juvenile inshore life-stage when they inhabit
more UV-exposed waters5,10. Even in an artificial transmission
setting, fibropapillomatosis tumors arose simultaneously,
regardless of the time of initial inoculation, only after tempera-
tures increased27. The authors attributed this to potential effects
of water temperature27, though this seasonality is also a proxy for
UV exposure. While our analysis focused on FL, UV exposure is
also altering globally as a result of climate change96. In the case of
fibropapillomatosis, UV exposure could be directly involved in
oncogenic transformation, as is the case for human skin cancers,
or alternatively could be acting through indirect mechanisms. For
instance, increased UV could contribute to immunosuppression
resulting in reduced control of ChHV5 infections95, increased
frequency of algal bloom events, which have been correlated with
fibropapillomatosis occurrence5,42–44,97, or UV radiation, which
can alter the chemical composition of contaminants in inshore
waters into carcinogenic forms98,99. Future research is required to
determine whether UV exposure is causally linked to fibropa-
pillomatosis tumor development, and if so, via which mechanism.
The genomic profiling reported here has improved our molecular
understanding of fibropapillomatosis by revealing the host sig-
naling pathways involved in tumors and indicating novel reha-
bilitation strategies for fibropapillomatosis-afflicted sea turtles.
Additionally, this study demonstrates the power of precision
medicine approaches47,48 to tackle rare or understudied diseases
for which there is limited background genetic knowledge, and
provides a proof-of-principle study for the emerging field of
precision wildlife medicine4.
Methods
Tissue sampling. Sampling was carried out under permit number MTP-17–236
from the Florida Fish and Wildlife Conservation Commission and with ethical





















Outcomes of FP eye tumor surgery (Sx), with and 








Fig. 7 Fibropapillomatosis eye tumor regrowth rates in the presence and absence of adjunct 5FU treatment. a Green sea turtles afflicted with
fibropapillomatosis eye tumors. b Fibropapilloma eye tumor regrowth rates, when treatment consists of surgical removal only, or surgical removal followed
by 8 weeks of topical 5-FU treatment. Total n= 121 turtles, with the number of turtles per condition inserted within the relevant section of each bar
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Committee (IACUC). Fibropapilloma tumors were surgically removed by laser
resection as part of the turtle’s rehabilitative care. All samples were obtained from
juvenile C. mydas, as this is the stage most afflicted by fibropapillomatosis5,10. As
juveniles, the sex of an individual is not readily determinable. However, one of the
turtles whose tumors were sequenced, Swoope (sp, patient ID: 02-2015-Cm), was
later determined to be male during necropsy, after being euthanized due to the
presence of internal tumors. Global gene expression of the tumors was compared
with that of non-tumored areas of the same turtles, obtained by 4 mm punch
biopsies during the tumor removal surgery. Non-tumored sites were selected by
gross examination of the region by the attending veterinarian and confirmed
visually to be tumor-free normal skin regions and not bordering any tumorous
regions by the attending vet technicians and researchers. Samples were stored in
RNA-later (Qiagen) at −80 °C, according to manufacturer’s instructions, for up to
3 months.
RNA extraction and RNA-seq. Total RNA was extracted using an RNeasy Kit
(Qiagen) according to manufacturer’s instructions. DNA was digested with DNA-
free Kit (Applied Biosystems). RNA quality was checked by RT-qPCR (as below)
and on a 2100 Bioanalyser (Agilent) using a Eukaryote Total RNA Nano Chip,
samples’ RIN value range 8.1–9.8. Ten RNA samples, comprising seven fibropa-
pillomatosis tumor samples (shoulder and neck cutaneous verrucous fibropa-
pilloma tumors) and three non-tumor samples, from two juvenile green turtles
(C. mydas), which had stranded in Northern FL were used for sequencing (Fig. 1b).
Sequencing libraries were generated from 500 ng of total RNA using the NEBNext
Ultra RNA Library Prep Kit for Illumina (New England Biolabs), including ployA
selection, according to manufacturer’s protocol. Size and purity of the libraries
were analyzed on a Bioanalyser High Sensitivity DNA chip (Agilent). Libraries
were paired-end sequenced with a read length of 75 bp a HiSeq 3000 (Illumina).
ERCC Spike-In Mix (ThermoFisher) was used as an internal control, 2 µL of 1:400
diluted ERCC Spike-In Mix with 500 ng of total RNA input.
Reads were trimmed with Trim Galore (https://www.bioinformatics.babraham.
ac.uk/projects/trim_galore/) to remove low-quality ends from reads in addition to
adapter removal. A de novo transcriptome was constructed from the sequencing
data using Trinity v2.1.150, specifying a minimum contig length of 300. Transcript
abundance was quantified with RSEM using bowtie2 for the alignment using the
align_and_estimate_abundance.pl script available through the Trinity toolkit. A
matrix of gene counts (genes.counts.matrix) and a matrix of TMM-normalized
expression values (TMM.EXPR.matrix) was constructed in RSEM using the
abundance_estimates_to_matrix.pl script available through the Trinity
toolkit100,101. A PCA plot (Fig. 1b) was generated using the PtR script in the
Trinity toolkit.
Prior to differential expression analysis, the genes.counts.matrix was processed
with the RUVseq Bioconductor package102 using the RUVs method to remove low
abundance genes, normalize the RNA-seq data, and remove unwanted variation.
The RUVseq-processed matrix was then used to identify DE transcripts using both
the EdgeR and DESeq2 Bioconductor packages. The resulting lists of DE genes
were sorted and filtered to include only those transcripts with false discovery rate
(EdgeR) or adjusted p-value (DESeq2) of <0.05 and log2 fold change of >2 or <−2.
A list of upregulated and downregulated transcripts that overlapped from both
analysis methods was generated and used to create area-proportional Venn
diagrams of overlap using BioVenn (http://www.biovenn.nl/) (Fig. 1c).
The retrieved gene lists were analyzed for overrepresented pathways, biological
functions, and upstream regulators using IPA (Ingenuity Systems, www.ingenuity.
com). p-Values reported for IPA results are generated by IPA using a right-sided
Fisher exact test for over-representation analysis, Benjamini–Hochberg correction
for multiple hypothesis testing correction, and a z-score algorithm for upstream
regulator analysis, p-values < 0.05 were considered significant. For the systems-level
analysis, the C. mydas DE transcripts were annotated to their closest characterized
human homolog. Human annotation was used to enable the most comprehensive
systems-level analysis, as human genes have been the most extensively annotated
and characterized.
To detect ChHV5 transcripts independently of our de novo transcriptome
analysis, trimmed reads (see above) were aligned to the ChHV5 partial genome
[GenBank accession number: HQ878327.2] using HISAT2 (https://ccb.jhu.edu/
software/hisat2/index.shtml)103. Aligned non-repetitive reads were blasted
(megablast, https://blast.ncbi.nlm.nih.gov/Blast.cgi) against the NCBI nucleotide
collection. These reads were specific to ChHV5 and their location within the
ChHV5 genome were visualized using Blast’s alignment graphics function (https://
goo.gl/YVQrkc).
Additional software tools and datasets: IPA software was used for the ITR,
pathway, and GO analysis. String (www.string-db.org) was used to generate
protein–protein interaction networks, and the KEGG pathway enrichment analysis
tool in String was also applied to these networks. Area-proportional Venn diagrams
were generated using BioVenn (http://www.biovenn.nl/). GeneMANIA (v3.5.0,
http://genemania.org/)104 was used to generate multiple association networks. UVI
data was obtained from publicly available NOOA datasets (http://www.ftp.cpc.
ncep.noaa.gov/long/uv/cities/ and http://www.cpc.ncep.noaa.gov/products/
stratosphere/uv_index/uv_annual.shtml). Stranding data was obtained from Foley
et al.73, with the raw data points generously provided directly to us by
Dr. Allen Foley.
RT-qPCR. RNA was extracted as above. Sixty-six tumor and 14 non-tumor RNA
samples from five juvenile green turtles (C. mydas), which had stranded in
Northern FL were used for cDNA was synthesis using a QuantiTect Reverse
Transcription Kit (Qiagen) including genomic DNA digestion. A LightCycler480
Instrument II (Roche) and LightCycler480 SYBR 1 Master reagents (Roche) were
used according to the manufacturer’s protocol. Cycling parameters were as follows:
95 °C 10 min, 45 cycles of 95 °C 10 s, 60 °C 20 s, 72 °C 20 s and a melting curve.
Primer sequences are provided in Table 1. Gene expression was normalized to the
expression of β-actin31 with Rplo (Table 1) as a second endogenous control.
Technical replicates for every sample were also performed. Upon admittance to the
hospital, the turtles used in the qPCR study had a tumor score range of 2–3
(Hawaii classification system)105, and a Southwest Atlantic fibropapillomatosis
(FPSSWA) tumor score range of mild to severe (fibropapillomatosis index, FPI,
range, 0.6 to >185.5) (Southwest Atlantic classification system)106.
Data availability. The RNA-seq data was deposited at NCBI (https://www.ncbi.
nlm.nih.gov/) under BioProject ID: PRJNA449022 (http://www.ncbi.nlm.nih.gov/
bioproject/449022), while the Transcriptome Shotgun Assembly project has been
deposited at DDBJ/EMBL-EBI/GenBankunder the accession GGMX00000000. The
version described in this paperis the first version, GGMX01000000.
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